Cargando…

Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Alarcon, Neftali Ortega, Jaramillo, Maddy, Mansour, Heidi M., Sun, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325128/
https://www.ncbi.nlm.nih.gov/pubmed/35890342
http://dx.doi.org/10.3390/pharmaceutics14071448
_version_ 1784756972264882176
author Alarcon, Neftali Ortega
Jaramillo, Maddy
Mansour, Heidi M.
Sun, Bo
author_facet Alarcon, Neftali Ortega
Jaramillo, Maddy
Mansour, Heidi M.
Sun, Bo
author_sort Alarcon, Neftali Ortega
collection PubMed
description For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and adjuvants are key components of vaccine formulations. We summarized several classes of tumor antigens and bioinformatic approaches of identification of tumor neoantigens. Pattern recognition receptor (PRR)-targeting adjuvants and their targeted delivery platforms have been extensively discussed. In addition, we emphasized the interplay between multiple adjuvants and their combined delivery for cancer immunotherapy.
format Online
Article
Text
id pubmed-9325128
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93251282022-07-27 Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms Alarcon, Neftali Ortega Jaramillo, Maddy Mansour, Heidi M. Sun, Bo Pharmaceutics Review For decades, vaccines have played a significant role in protecting public and personal health against infectious diseases and proved their great potential in battling cancers as well. This review focused on the current progress of therapeutic subunit vaccines for cancer immunotherapy. Antigens and adjuvants are key components of vaccine formulations. We summarized several classes of tumor antigens and bioinformatic approaches of identification of tumor neoantigens. Pattern recognition receptor (PRR)-targeting adjuvants and their targeted delivery platforms have been extensively discussed. In addition, we emphasized the interplay between multiple adjuvants and their combined delivery for cancer immunotherapy. MDPI 2022-07-11 /pmc/articles/PMC9325128/ /pubmed/35890342 http://dx.doi.org/10.3390/pharmaceutics14071448 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alarcon, Neftali Ortega
Jaramillo, Maddy
Mansour, Heidi M.
Sun, Bo
Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
title Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
title_full Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
title_fullStr Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
title_full_unstemmed Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
title_short Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
title_sort therapeutic cancer vaccines—antigen discovery and adjuvant delivery platforms
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325128/
https://www.ncbi.nlm.nih.gov/pubmed/35890342
http://dx.doi.org/10.3390/pharmaceutics14071448
work_keys_str_mv AT alarconneftaliortega therapeuticcancervaccinesantigendiscoveryandadjuvantdeliveryplatforms
AT jaramillomaddy therapeuticcancervaccinesantigendiscoveryandadjuvantdeliveryplatforms
AT mansourheidim therapeuticcancervaccinesantigendiscoveryandadjuvantdeliveryplatforms
AT sunbo therapeuticcancervaccinesantigendiscoveryandadjuvantdeliveryplatforms